Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Clay

Showing results (131-140 of 174) with videos related to

Pageof 18
Sort By:
Plos One|August 14, 2008
Microarray analysis of human monocytes infected with Francisella tularensis identifies new targets of host response subversionJonathan P Butchar, Thomas J Cremer, Corey D Clay, et al.
Pathology|March 30, 2016
Associations between the IASLC/ATS/ERS lung adenocarcinoma classification and EGFR and KRAS mutationsT D Clay, P A Russell, H Do, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 12, 2014
The clinical relevance of pathologic subtypes in metastatic lung adenocarcinomaTimothy D Clay, Hongdo Do, Vijaya Sundararajan, et al.
Lancet (London, England)|October 6, 2009
The role of academic health science systems in the transformation of medicineVictor J Dzau, D Clay Ackerly, Pamela Sutton-Wallace, et al.
JCO Precision Oncology|February 1, 2022
MEK Inhibitor Therapy in Carcinomas With <i>RAF1</i> Fusions: Inferior Response in a Patient With Pancreatic Acinar Cell CarcinomaChristopher R McEvoy, Damien Kee, Owen W J Prall, et al.
Free Radical Biology & Medicine|February 26, 2004
Uncoupling-mediated generation of reactive oxygen by halogenated aromatic hydrocarbons in mouse liver microsomesHoward G Shertzer, Corey D Clay, Mary Beth Genter, et al.
Pathology|December 5, 2013
EGFR gene copy number alterations are not a useful screening tool for predicting EGFR mutation status in lung adenocarcinomaPrudence A Russell, Yong Yu, Hongdo Do, et al.
Immunotherapy|February 25, 2025
Immunotherapy rechallenge after significant toxicity - can it be done successfully?Ashley Tan, Tara McSweeney, Nisha Sikotra, et al.
Medical Oncology (Northwood, London, England)|September 8, 2017
EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinomaTimothy D Clay, Prudence A Russell, Hongdo Do, et al.
Academic Medicine : Journal of the Association of American Medical Colleges|March 26, 2011
Training the next generation of physician-executives: an innovative residency pathway in management and leadershipD Clay Ackerly, Devdutta G Sangvai, Krishna Udayakumar, et al.
Pageof 18

Showing results (131-140 of 174) with videos related to

Sort By:
Pageof 18
Plos One|August 14, 2008
Microarray analysis of human monocytes infected with Francisella tularensis identifies new targets of host response subversionJonathan P Butchar, Thomas J Cremer, Corey D Clay, et al.
Pathology|March 30, 2016
Associations between the IASLC/ATS/ERS lung adenocarcinoma classification and EGFR and KRAS mutationsT D Clay, P A Russell, H Do, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 12, 2014
The clinical relevance of pathologic subtypes in metastatic lung adenocarcinomaTimothy D Clay, Hongdo Do, Vijaya Sundararajan, et al.
Lancet (London, England)|October 6, 2009
The role of academic health science systems in the transformation of medicineVictor J Dzau, D Clay Ackerly, Pamela Sutton-Wallace, et al.
JCO Precision Oncology|February 1, 2022
MEK Inhibitor Therapy in Carcinomas With <i>RAF1</i> Fusions: Inferior Response in a Patient With Pancreatic Acinar Cell CarcinomaChristopher R McEvoy, Damien Kee, Owen W J Prall, et al.
Free Radical Biology & Medicine|February 26, 2004
Uncoupling-mediated generation of reactive oxygen by halogenated aromatic hydrocarbons in mouse liver microsomesHoward G Shertzer, Corey D Clay, Mary Beth Genter, et al.
Pathology|December 5, 2013
EGFR gene copy number alterations are not a useful screening tool for predicting EGFR mutation status in lung adenocarcinomaPrudence A Russell, Yong Yu, Hongdo Do, et al.
Immunotherapy|February 25, 2025
Immunotherapy rechallenge after significant toxicity - can it be done successfully?Ashley Tan, Tara McSweeney, Nisha Sikotra, et al.
Medical Oncology (Northwood, London, England)|September 8, 2017
EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinomaTimothy D Clay, Prudence A Russell, Hongdo Do, et al.
Academic Medicine : Journal of the Association of American Medical Colleges|March 26, 2011
Training the next generation of physician-executives: an innovative residency pathway in management and leadershipD Clay Ackerly, Devdutta G Sangvai, Krishna Udayakumar, et al.
Pageof 18